A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer's disease, demonstrating its ability to mitigate brain damage and improve cognitive functions in mouse models. A forthcoming clinical trial aims to test its efficacy in humans.
Most current treatments for Alzheimer's disease focus on addressing amyloid plaques and tau tangles in the brain. However, researchers from Mass General Brigham and Washington University School of Medicine in St. Louis have identified a groundbreaking alternative: Xenon gas.
Their study demonstrated that inhaling Xenon gas reduced neuroinflammation, minimized brain atrophy, and promoted protective neuronal states in mouse models of Alzheimer's disease. These findings, published today (January 15) in Science Translational Medicine, have paved the way for a phase 1 clinical trial in healthy volunteers, set to begin in early 2025.
Groundbreaking Research and Clinical Trials
"It is a very novel discovery showing that simply inhaling an inert gas can have such a profound neuroprotective effect," said senior and co-corresponding author Oleg Butovsky, PhD, of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital (BWH), a founding member of the Mass General Brigham healthcare system. "One of the main limitations in the field of Alzheimer's disease research and treatment is that it is extremely difficult to design medications that can pass the blood-brain barrier—but Xenon gas does. We look forward to seeing this novel approach tested in humans."
"It is exciting that in both animal models that model different aspects of Alzheimer's disease, amyloid pathology in one model and tau pathology in another model, that Xenon had protective effects in both situations," said senior and co-corresponding author David M. Holtzman, MD, from Washington University School of Medicine in St. Louis.
The Science Behind Xenon's Effects
The exact causes of Alzheimer's disease remain unclear, and there is currently no cure. More effective treatments are urgently needed. Alzheimer's is marked by the buildup of proteins in the brain, such as tau and amyloid, which disrupt nerve cell communication. Over time, this leads to progressive brain damage, neuronal loss, and ultimately, death.
Microglia, the brain's primary immune cells, act as the brain's first line of defense, responding to any disruptions and playing a crucial role in maintaining brain function throughout life. However, when microglia become dysregulated, they contribute significantly to the progression of Alzheimer's disease. Research from Dr. Butovsky's lab has developed a method to study microglial responses to neurodegeneration, revealing that certain microglial phenotypes can be modulated to provide protective effects against Alzheimer's.
In this study, mouse models of Alzheimer's disease were treated with Xenon gas that has been used in human medicine as an anesthetic and as a neuroprotectant for treating brain injuries. Xenon gas penetrates the blood-brain barrier, passing from the bloodstream directly into the fluid surrounding the brain. The team found that Xenon gas inhalation reduced brain atrophy and neuroinflammation and improved nest-building behaviors in the Alzheimer's disease mouse models. It also induced and increased a protective microglial response that is associated with clearing amyloid and improving cognition. Together, these findings identify the promising potential of Xenon inhalation as a therapeutic approach that could modify microglial activity and reduce neurodegeneration in Alzheimer's disease.
Future Directions and Clinical Potential
The clinical trial at Brigham and Women's Hospital, which will initially only enroll healthy volunteers, is set to begin in the next few months.
As early phases of the clinical trial get underway to establish safety and dosage, the research team plans to continue to study the mechanisms by which Xenon gas achieves its effects in addition to its potential for treating other diseases such as multiple sclerosis, amyotrophic lateral sclerosis, and eye diseases that involve the loss of neurons. The team is also devising technologies to help use Xenon gas more efficiently as well as potentially recycle it.
"If the clinical trial goes well, the opportunities for the use of Xenon gas are great," said co-author Howard Weiner, MD, co-director of the Ann Romney Center for Neurologic Diseases at BWH and principal investigator of the upcoming clinical trial. "It could open the door to new treatments for helping patients with neurologic diseases."
Reference: "Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy" by Wesley Brandao, Nimansha Jain, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Xin Bao, Javier R. Serrano, Eric Tycksen, Ana Durao, Jen-Li Barry, Caroline Baufeld, Dilansu Guneykaya, Xiaoming Zhang, Alexandra Litvinchuk, Hong Jiang, Neta Rosenzweig, Kristen M. Pitts, Michael Aronchik, Taha Yahya, Tian Cao, Marcelo Kenzo Takahashi, Rajesh Krishnan, Hayk Davtyan, Jason D. Ulrich, Mathew Blurton-Jones, Ilya Ilin, Howard L. Weiner, David M. Holtzman and Oleg Butovsky, 15 January 2025, Science Translational Medicine.
DOI: 10.1126/scitranslmed.adk3690
Authorship: In addition to Butovsky and Weiner, Mass General Brigham authors include Wesley Brandao, Zhuoran Yin, Kilian L. Kleemann, Madison Carpenter, Ana Durao, Jen-Li Barry, Caroline Baufeld, Dilansu Guneykaya, Xiaoming Zhang, Neta Rosenzweig, Kristen M. Pitts, Michael Aronchik, Taha Yahya, Tian Cao, Marcelo Kenzo Takahashi, Rajesh Krishnan, Additional authors include Nimansha Jain, Xin Bao, Javier R. Serrano, Eric Tycksen, Alexandra Litvinchuk, Hong Jiang, Hayk Davtyan, Jason D. Ulrich, Mathew Blurton-Jones, Ilya Ilin, and David M. Holtzman.
Disclosures: Butovsky, Ilin, Weiner, Yin, and Brandao are co-inventors on patent no. 17/914,061 (held by Brigham and Women's Hospital and General Biophysics) for using Xe to treat neurodegenerative diseases. Butovsky is co-founder and is on the scientific advisory board of Glial Therapeutics and GliaX; collaborates with GSK and Regulus Therapeutics; has research funding from Sanofi, GSK; and consults for/has received honoraria from UCB, Camp4, Ono Pharma USA, General Biophysics. Holtzman co-founded and is on the scientific advisory board of C2N Diagnostics. Holtzman is on the scientific advisory board of Denali, Genentech, and Cajal Neurosciences and consults for Asteroid Therapeutics. Blurton-Jones co-founded and is on the scientific advisory board of NovoGlia Inc. Ilin is the founder and CEO of General Biophysics LLC.
Funding: This study was funded by National Institutes of Health (NIH) (STTR R41AG073059, R01 AG051812 R01 AG054672, R01 NS088137 R01 AG075509, RF1 NS090934, P30 AG066519, U19 AG06970101); Cure Alzheimer Fund; Massachusetts Center for Alzheimer Therapeutic Science (MassCATS); BrightFocus Foundation 2020A016806; Alzheimer's Association research fellowship AARF-21-846786; National Multiple
Sclerosis Society FG-2108-38372; Department of Defense W81XWH-22-1-0945
News
Breakthrough Diabetes Treatment Reprograms the Immune System
An engineered stem cell therapy reversed new-onset Type 1 diabetes in mice by shifting the immune system away from attacking insulin-producing cells. For more than a century, people with Type 1 diabetes have relied [...]
Taking the world’s temperature: WHO chief spotlights global health emergencies
Taking the world’s temperature on pressing health matters, WHO Director-General Tedros Adhanom Ghebreyesus provided the latest on current global challenges - and successes when it comes to international cooperation. “The outbreaks of hantavirus, Ebola and Marburg all show [...]
Scientists Create Tiny “Mini Livers” That Could One Day Replace Liver Transplants
Engineered tissue grafts could help perform key liver functions and benefit thousands of people living with liver failure. The liver is one of the body’s hardest-working organs, carrying out hundreds of vital jobs, from [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
Scientists Discover Surprising Way To Help the Brain Recover After Stroke
A new study suggests that strengthening the body’s natural circadian rhythms may help the brain recover after stroke, even when treatment begins days after the injury. Every year, millions of people survive a stroke, [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Younger Generations Are Aging Faster – and It May Be Fueling a Surge in Cancer
Younger generations may be aging biologically faster than those before them, and that shift could help explain rising rates of cancer at younger ages. For decades, cancer was viewed largely as a disease of [...]
Using Cannabis Could Raise Your Stroke Risk by 37%, Massive Study Reveals
Large-scale evidence suggests cannabis, cocaine, and amphetamines may directly raise stroke risk, including in younger adults. As recreational drug use becomes increasingly common, researchers are uncovering evidence that its health consequences may extend far beyond [...]
Could Vitamin C Be the Secret to Keeping Your Brain Younger?
Lower vitamin C levels were linked to reduced brain volume and weaker neural connectivity in older adults, suggesting a potential connection between nutrition and brain health. Could a common vitamin help preserve the brain [...]
This Deadly Disease Was Wiping Out Humans 5,500 Years Ago
A new study suggests plague was already a deadly threat 5,500 years ago, striking small hunter-gatherer communities long before cities and agriculture emerged. For centuries, plague has been remembered as the disease that devastated [...]
China closing in but US leads in biotech quality, commercial reach, survey finds
SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials, opens new tab than the U.S., still lags in the quality and commercial reach of its biomedical science, according to a recent survey, opens new [...]
New method generates renewable supply of progenitor immune cells
In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages. These immune cells help [...]
Scientists Just Discovered a Cellular Survival System That Was Never Supposed To Exist
A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails. For decades, biologists believed cells had only one way to access a molecule they cannot live without. New [...]
Artificial cells gain porous membranes, enabling lab reactions and drug release
Artificial cells created in the laboratory offer a wide range of potential applications. Until now, however, their membranes—unlike those of real cells—have been virtually impermeable. Researchers at the Max Planck Institute for Polymer Research, [...]
Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, [...]
Stanford Scientists Discover Explosive New Type of Immune Cell
Scientists studying the remarkable regenerative abilities of planarian flatworms have uncovered a previously unknown type of immune cell with an unusually destructive defense strategy. What if an immune cell could wipe out nearby threats [...]
